A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
暂无分享,去创建一个
Werner Poewe | Fabrizio Stocchi | Anthony Lang | Olivier Rascol | Joseph Jankovic | J. Jankovic | E. Tolosa | W. Poewe | O. Rascol | A. Lang | R. Hauser | C. Olanow | E. Melamed | P. Feigin | F. Stocchi | W. Langston | Eduardo Tolosa | C Warren Olanow | Robert Hauser | Paul D Feigin | William Langston | Eldad Melamed
[1] C. Clarke. Are delayed‐start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? , 2008, Movement disorders : official journal of the Movement Disorder Society.
[2] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[3] J. Jankovic,et al. A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics , 2008, Movement disorders : official journal of the Movement Disorder Society.
[4] G. Nappi,et al. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease , 2004, Experimental Neurology.
[5] Y. Hochberg. A sharper Bonferroni procedure for multiple tests of significance , 1988 .
[6] S Fahn,et al. Committee. Unified Parkinson’s Disease Rating Scale. , 2001 .
[7] T. Amit,et al. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro , 2007, Journal of neurochemistry.
[8] A. Schapira,et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial , 2006, The Lancet Neurology.
[9] J. Nutt,et al. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. , 2002, Archives of neurology.
[10] A. Schapira,et al. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. , 2004, JAMA.
[11] S. Mandel,et al. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives , 2005, Brain Research Reviews.
[12] A. Bonnet,et al. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.
[13] J. Hubble,et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease , 1995, Annals of neurology.
[14] W Poewe,et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.
[15] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan , 2007, Movement disorders : official journal of the Movement Disorder Society.
[16] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[17] W Tatton,et al. The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo , 2001, Annals of the New York Academy of Sciences.
[18] W. Tatton,et al. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. , 2000, Molecular pharmacology.
[19] P Leber,et al. Observations and Suggestions on Antidementia Drug Development , 1996, Alzheimer disease and associated disorders.
[20] J. Obeso,et al. Timing of treatment initiation in Parkinson's disease: A need for reappraisal? , 2006, Annals of neurology.
[21] C. Olanow,et al. The scientific basis for the current treatment of Parkinson's disease. , 2004, Annual review of medicine.
[22] M. Youdim,et al. Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[23] A. Siderowf,et al. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. , 2004, Archives of neurology.
[24] C. Marsden,et al. Recent Developments in Parkinson's Disease , 1986 .
[25] W. Poewe,et al. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy , 2008, Experimental Neurology.
[26] M. Hely,et al. Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.
[27] M. Youdim,et al. Novel Neuroprotective Mechanism of Action of Rasagiline Is Associated with Its Propargyl Moiety: Interaction of Bcl‐2 Family Members with PKC Pathway , 2005, Annals of the New York Academy of Sciences.
[28] S. Mandel,et al. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism , 2007, Neurobiology of Disease.
[29] P Leber,et al. Slowing the progression of Alzheimer disease: methodologic issues. , 1997, Alzheimer disease and associated disorders.